Cormorant Pharmaceuticals

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
See more in Biomedtracker

Latest on Cormorant Pharmaceuticals

In Vivo

Biopharma Quarterly Dealmaking Statistics, Q3 2016

 
• By Amanda Micklus and Maureen Riordan

Financings Third-quarter 2016 biopharma financing totaled $7.4 billion, a 54% increase over Q2’s $4.8 billion. Follow-on public offerings were again the lead financing vehicle, bringing in $3.36 billi

In Vivo

Deals Shaping the Medical Industry, August 2016

 
• By Beth Allan, Deanna Kamienski, Amanda Micklus, Steven Muntner, and Maureen Riordan

IN VITRO DIAGNOSTICS Alliances Cleveland HeartLab LLC Global Discovery Biosciences Global Discovery Biosciences licensed Cleveland HeartLab Inc. exclusive rights to distribute its PULS ( Prote

Pink Sheet

Deal Watch: Medivation Enters Confidential Talks With Suitors, Including Sanofi

 
• By Joseph Haas

The Pink Sheet regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between July 2-7. D

Pink Sheet

BMS Scoops Cormorant In $520M Immuno-Oncology Deal

US pharma giant Bristol-Myers Squibb Co. continues to reinforce its burgeoning immuno-oncology franchise with the $520M acquisition of Cormorant Pharmaceuticals AB , a private Swedish biotech w